Which trial do we need? Defining the optimal duration of antifungal therapy for invasive pulmonary aspergillosis.
- DOI
- 10.1016/j.cmi.2026.01.030
- Published
- 2026 May
- Container
- Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.cmi.2026.01.030,
title = {Which trial do we need? Defining the optimal duration of antifungal therapy for invasive pulmonary aspergillosis.},
author = {Desoubeaux G and Mikulska M and Lemaignen A and Gyan E and Stemler J and Vanbiervliet Y and Maertens J and Lortholary O and Paccoud O and Slavin MA and Cornely OA and Neofytos D and Lanternier F},
year = {2026},
journal = {Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases},
doi = {10.1016/j.cmi.2026.01.030},
url = {https://doi.org/10.1016/j.cmi.2026.01.030}
}RIS
TY - JOUR TI - Which trial do we need? Defining the optimal duration of antifungal therapy for invasive pulmonary aspergillosis. AU - Desoubeaux G AU - Mikulska M AU - Lemaignen A AU - Gyan E AU - Stemler J AU - Vanbiervliet Y AU - Maertens J AU - Lortholary O AU - Paccoud O AU - Slavin MA AU - Cornely OA AU - Neofytos D AU - Lanternier F PY - 2026 JO - Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases DO - 10.1016/j.cmi.2026.01.030 UR - https://doi.org/10.1016/j.cmi.2026.01.030 ER -
APA
G, D., M, M., A, L., E, G., J, S., Y, V., J, M., O, L., O, P., MA, S., OA, C., D, N., & F, L. (2026). Which trial do we need? Defining the optimal duration of antifungal therapy for invasive pulmonary aspergillosis.. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. https://doi.org/10.1016/j.cmi.2026.01.030
Source records
- pubmed · retrieved 2026-09-27T14:01:37.309Z